Natural analogues inhibiting selective cyclin-dependent kinase protein isoforms: a computational perspective. Issue 17 (21st November 2020)

• Record Type: Journal Article
• Authors: Singh, Rahul; Bhardwaj, Vijay; Das, Pralay; Purohit, Rituraj
• Is Part Of: Journal of biomolecular structure & dynamics. Volume 38:Issue 17(2020)
• Page Start: 5126
• Page End: 5135
• Publication Date: 2020-11-21
• Subjects: CDK isoforms -- pyrrolone-fused benzosuberene (PBS) -- MM-PBSA -- drug discovery -- ligand efficiency; Biomolecules -- Periodicals; Molecular structure -- Periodicals; Molecular Biology -- Periodicals; Biomechanics -- Periodicals; 572
• DOI: 10.1080/07391102.2019.1696709
• Languages: English
• ISSNs: 0739-1102

Abstract

Abstract: Cyclin-dependent kinases (CDKs) are known for their vital role in regulating cell cycle progression through protein-kinase interactions. CDKs also help in regulating transcription and development of the central nervous system. Inhibition of CDKs is a very fundamental approach for drug discovery in areas of different types of cancers, Alzheimer's, and HIV infections. The present research focuses on finding a novel, potent, and specific natural inhibitors of CDK isoforms (CDK2, CDK5, CDK7, CDK9). Molecular docking, molecular dynamics (MD) simulations, and Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) were carried out to get an in-depth understanding of protein–ligand interactions. Based on our molecular docking results, Ligands-3, 5, 14, and 16 were screened among 17 different Pyrrolone-fused benzosuberene compounds as potent and specific inhibitors without any cross-reactivity against different CDK isoforms. Analysis of MD simulations and MM-PBSA studies, revealed the binding energy profiles of all the selected complexes. Our selected ligands performed better than the standard inhibitor (Roscovitine). Ligands-3 and 14 show specificity for CDK7 and Ligands-5 and 16 were specific against CDK9. These ligands are expected to possess lower risk of side effects due to their natural origin. Moreover, the backbone structure of these ligands could also be exploited to develop specific inhibitors against other CDK isoforms. Communicated by Ramaswamy H. Sarma